Romosozumab in older adults: real-world patterns in fracture liaison service cohort
Authors' conclusion
In this descriptive older adults FLS cohort, romosozumab recipients represented a higher-risk phenotype but showed broadly similar 12-month clinical trajectories compared with other therapies; monthly romosozumab showed high 12-month treatment completion and broadly similar short-term clinical trajectories to other treatment pathways
Study context
- Population
- Older adults at imminent fracture risk (≥ 1 fragility fracture within 24 months before baseline) initiating osteoporosis therapy, Hospital Universitario de Navarra fracture liaison service (FLS), 2022–2024n = 17/group
- Participants
- 68 adults
- Exposure
- Romosozumab vs denosumab, zoledronic acid and teriparatide
- Romosozumabn = 17
- Denosumabn = 17
- Zoledronic acidn = 17
- Teriparatiden = 17
- Outcome
- Scheduled-treatment completion
- Follow-up
- 12 months
Methodological detailssingle-center, observational, descriptive, calendar-time matched selection
- Single-center
- Observational
- Descriptive
- Calendar-time matched selection
Main finding
As reported in the abstract
Scheduled-treatment completion among evaluable patients
P = 0.016
Observational data: associations, not effects.
Further findings
Baseline estimated fracture risk (FRAX/QFracture)
- Higher in anabolic-treated groups
Mortality, emergency visits, admissions, falls, fractures · over follow-up
- No significant between-group differences
Treatment sequencing · 12 months
- Differed significantly, with heterogeneous post-index regimens after romosozumab and after teriparatide
Safety
Adverse drug reactions · over follow-up
- Infrequent; no significant between-group differences
Original publication
Romosozumab in older adults: real-world patterns in fracture liaison service cohort. Osteoporos Int. Published 11 August 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →